Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Usgena“
Suchtreffer
Begriffe & Kennungen
Usgena · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenUsgena · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenUsgena · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenUsgena · 4.8 · Respiratory, thoracic and Common: Oropharyngeal pain mediastinal disorders Uncommon: Nasal congestion Rare: Al
Eintrag öffnenUsgena · 4.8 · Skin and subcutaneous tissue Common: Pruritus disorders Uncommon: Pustular psoriasis, skin exfoliation, acne R
Eintrag öffnenUsgena · 4.8 · Summary of the safety profile
Eintrag öffnenUsgena · 4.8 · Summary of the safety profile
Eintrag öffnenUsgena · 4.8 · Table 2 List of adverse reactions System Organ Class Frequency: Adverse reaction
Eintrag öffnenUsgena · 4.8 · Table 2 provides a list of adverse reactions from adult psoriasis, psoriatic arthritis, Crohn’s disease and ul
Eintrag öffnenUsgena · 4.8 · Table 3 List of adverse reactions System Organ Class Frequency: Adverse reaction
Eintrag öffnenUsgena · 4.8 · Table 3 provides a list of adverse reactions from adult psoriasis, psoriatic arthritis, Crohn’s disease and ul
Eintrag öffnenUsgena · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenUsgena · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenUsgena · 4.8 · The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis, Cr
Eintrag öffnenUsgena · 4.8 · The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis, Cr
Eintrag öffnenUsgena · 4.8 · The safety data described below reflect exposure in adults to ustekinumab in 14 phase 2 and phase 3 studies in
Eintrag öffnenUsgena · 4.8 · The safety data described below reflect exposure in adults to ustekinumab in 14 phase 2 and phase 3 studies in
Eintrag öffnen